Diazoxide choline controlled release regulatory update

FDA granted Orphan Drug designation to Essentialis’ diazoxide choline controlled release (DCCR) to treat Prader-Willi syndrome. The ATP-dependent potassium channel (KATP) agonist is in Phase I testin...